Contrast-enhanced MRI in Detecting Benign and Malignant Liver Lesions

• Status: Recruiting
• Trial end date: 2021-10-31
• Target enrollment: 0
• Participant gender: All

Summary

This clinical trial studies contrast-enhanced magnetic resonance imaging (MRI) in detecting nonmalignant and malignant liver lesions. Diagnostic procedures, such as MRI, may help find and diagnose nonmalignant and malignant liver lesions. Contrast agents, such as gadoxetate disodium and gadobutrol, may help doctors to see MRI images more clearly.

• Phase: N/A
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: M.D. Anderson Cancer Center
• Collaborator: National Cancer Institute (NCI)
• Treatments: Edetic Acid; Pentetic Acid

Criteria

Inclusion Criteria:

• Patients with the most recent abdominal magnetic resonance (MR) study obtained within 3 months +/- 1 week

• Patients with renal function (estimated glomerular filtration rate [eGFR] >= 30)

• Any disease type

Exclusion Criteria:

• Pregnant women

• Patients with impaired renal function (eGFR < 30)

• Patients with surgical implants and/or metallic foreign bodies non-compatible with the MR magnet

• Patients with contraindications to the use of intravenous contrast such as allergic type reactions